Condition: Locally Recurrent Skin Squamous Cell Carcinoma · Metastatic Skin Squamous Cell Carcinoma · Sponsor: National Cancer Institute (NCI)
This phase II trial compares the effect of amivantamab and hyaluronidase to cetuximab for the treatment of skin (cutaneous) squamous cell carcinoma that has come back after a period of improvement and has not spread to other parts of the body (locally recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Amivantamab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Hyaluronidase is an endoglycosidase. It helps to keep amivantamab in the body longer, so that the medications will have a greater effect. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of cancer cells. This may help keep cancer cells from growing. Giving amivantamab and hyaluronidase may be as effective as cetuximab for the treatment of locally recurrent or metastatic cutaneous squamous cell carcinoma.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham Cancer Center | Birmingham, Alabama, United States | Recruiting |
| Banner MD Anderson Cancer Center | Gilbert, Arizona, United States | Recruiting |
| UC San Diego Moores Cancer Center | La Jolla, California, United States | Recruiting |
| Yale University | New Haven, Connecticut, United States | Recruiting |
| Smilow Cancer Hospital Care Center-Trumbull | Trumbull, Connecticut, United States | Recruiting |
| Smilow Cancer Hospital Care Center - Waterford | Waterford, Connecticut, United States | Recruiting |
| University of Chicago Comprehensive Cancer Center | Chicago, Illinois, United States | Recruiting |
| Carle at The Riverfront | Danville, Illinois, United States | Recruiting |
| Carle Physician Group-Effingham | Effingham, Illinois, United States | Recruiting |
| Carle Physician Group-Mattoon/Charleston | Mattoon, Illinois, United States | Recruiting |
| UC Comprehensive Cancer Center at Silver Cross | New Lenox, Illinois, United States | Recruiting |
| Carle BroMenn Medical Center | Normal, Illinois, United States | Recruiting |
+ 26 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07042295